A phase III, randomised, double-blind, placebo-controlled, multicentre trial comparing efficacy and safety of trilaciclib versus placebo in participants with limited-stage small cell lung cancer
Sponsor: Pharmacosmos A/S
Phase: 3
Disease: Limited-stage small cell lung cancer
EU trial number: 2025-525026-35-00
Population: Adults with histologically or cytologically confirmed limited-stage small cell lung cancer (stage I–III without distant metastases), ECOG performance status 0–1, measurable or evaluable disease, and eligibility for first-line concurrent platinum/etoposide chemoradiotherapy.
Register Investigator Interest
Interested in offering this trial to suitable patients?